PHARMACOLOGICALLY OPTIMIZED TLR5 AGONIST AS A NOVEL AGAINST IDIOPATHIC PULMONARY FIBROSIS

$2,999,036FY2020Defense Health AgencyDOD

Genome Protection Inc

Investigators

PHARMACOLOGICALLY OPTIMIZED TLR5 AGONIST AS A NOVEL AGAINST IDIOPATHIC PULMONARY FIBROSIS · GrantIndex